Show simple item record

dc.contributor.authorO Riain, C
dc.contributor.authorO Shea, DM
dc.contributor.authorYang, Y
dc.contributor.authorLe Dieu, R
dc.contributor.authorGribben, JG
dc.contributor.authorSummers, K
dc.contributor.authorYeboah-Afari, J
dc.contributor.authorBhaw-Rosun, L
dc.contributor.authorFleischmann, C
dc.contributor.authorMein, CA
dc.contributor.authorCrook, T
dc.contributor.authorSmith, P
dc.contributor.authorKelly, G
dc.contributor.authorRosenwald, A
dc.contributor.authorOtt, G
dc.contributor.authorCampo, E
dc.contributor.authorRimsza, LM
dc.contributor.authorSmeland, EB
dc.contributor.authorChan, WC
dc.contributor.authorJohnson, N
dc.contributor.authorGascoyne, RD
dc.contributor.authorReimer, S
dc.contributor.authorBraziel, RM
dc.contributor.authorWright, GW
dc.contributor.authorStaudt, LM
dc.contributor.authorLister, TA
dc.contributor.authorFitzgibbon, J
dc.date.accessioned2018-08-29T08:38:28Z
dc.date.issued2009-10
dc.identifier10
dc.identifier.citationLEUKEMIA, 2009, 23 pp. 1858 - 1866
dc.identifier.issn0887-6924
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2394
dc.identifier.doi10.1038/leu.2009.114
dc.description.abstractQuantitative methylation profiling was performed using the Illumina GoldenGate Assay in untreated follicular lymphoma (FL) (164), paired pre- and post-transformation FL (20), benign haematopoietic (24) samples and purified B and T cells from two FL cases. Methylation values allowed separation of untreated FL samples from controls with one exception, based primarily on tumour-specific gains of methylation typically occurring within CpG islands. Genes that are targets for epigenetic repression in stem cells by Polycomb Repressor Complex 2 were significantly over-represented among hypermethylated genes. Methylation profiles were conserved in sequential FL and t-FL biopsies, suggesting that widespread methylation represents an early event in lymphomagenesis and may not contribute substantially to transformation. A significant (P<0.05) correlation between FL methylation values and reduced gene expression was shown for up to 28% of loci. Methylation changes occurred predominantly in B cells with variability in the amount of non-malignant tissue between samples preventing conclusive correlation with survival. This represents an important caveat in attributing prognostic relevance to methylation and future studies in cancer will optimally require purified tumour populations to address the impact of methylation on clinical outcome. Leukemia (2009) 23, 1858-1866; doi: 10.1038/leu.2009.114; published online 9 July 2009
dc.format.extent1858 - 1866
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUP
dc.titleArray-based DNA methylation profiling in follicular lymphoma
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/leu.2009.114
rioxxterms.licenseref.startdate2009-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfLEUKEMIA
pubs.notesaffiliation: O’Riain, C (Reprint Author), Barts & London Queen Marys Sch Med & Dent, Ctr Med Oncol, Inst Canc, 3rd Floor,John Vane Sci Bldg,Charterhouse Sq, London EC1M 6BQ, England. O’Riain, C.; O’Shea, D. M.; Yang, Y.; Le Dieu, R.; Gribben, J. G.; Summers, K.; Lister, T. A.; Fitzgibbon, J., Barts & London Queen Marys Sch Med & Dent, Ctr Med Oncol, Inst Canc, London EC1M 6BQ, England. Yeboah-Afari, J.; Bhaw-Rosun, L.; Fleischmann, C.; Mein, C. A., Barts & London Queen Marys Sch Med & Dent, Genome Ctr, London, England. Crook, T.; Smith, P., Inst Canc Res, London SW3 6JB, England. Kelly, G., Lincolns Inn Fields, Macrophage Lab, Lincolns Inn Fields, Canc Res UK, London WC2A 3PX, England. Rosenwald, A.; Ott, G., Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany. Ott, G., Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany. Campo, E., Univ Barcelona, Dept Pathol, Hosp Clin, Barcelona, Spain. Rimsza, L. M., Univ Arizona, Ctr Canc, Dept Pathol, Tucson, AZ USA. Smeland, E. B., Univ Hosp, Rikshosp, Inst Canc Res, Dept Immunol, Oslo, Norway. Smeland, E. B., Univ Oslo, Norwegian Radium Hosp, Ctr Canc Biomed, Fac Div, Oslo, Norway. Chan, W. C., Univ Nebraska, Med Ctr, Dept Pathol, Omaha, NE USA. Johnson, N.; Gascoyne, R. D., British Columbia Canc Res Ctr, Dept Pathol, Vancouver, BC V5Z 1L3, Canada. Reimer, S.; Braziel, R. M., Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. Wright, G. W.; Staudt, L. M., NCI, Metab Branch, Bethesda, MD 20892 USA. keywords: methylation; follicular lymphoma; gene expression; polycomb; transformation keywords-plus: B-CELL LYMPHOMA; NON-HODGKINS LYMPHOMAS; EMBRYONIC STEM-CELLS; COLORECTAL-CANCER; PROMOTER HYPERMETHYLATION; INSTRUCTIVE MECHANISM; UNIPARENTAL DISOMY; GENE-EXPRESSION; TRANSFORMATION; POLYCOMB research-areas: Oncology; Hematology web-of-science-categories: Oncology; Hematology author-email: [email protected] researcherid-numbers: Wright, George/M-1660-2017 orcid-numbers: Mein, Charles/0000-0003-0811-9658 Campo, elias/0000-0001-9850-9793 Kelly, Gavin/0000-0001-7219-560X funding-acknowledgement: Cancer Research UK [MONG1E9R]; Medical Research Council Clinical Research Fellowships; Cancer Research UK; NHS [ONAG1G5R]; National Institute of Health Strategic Partnering for Evaluation of Cancer Signatures Program (SPECS) [5 U01 CA114778] funding-text: We are grateful for the assistance of Sameena Iqbal, Andrew Davies (Institute of Cancer, London) and Susan Oliver (Oregon Health and Sciences University), for the critical review of manuscript by Emanuela Carlotti and Carolyn Owen (Institute of Cancer, London) and for helpful discussion with Attilla Lorincz (Wolfson Institute, London), Gerd Pfeifer (City of Hope, California) and Allen Yang (University of Southern California). We also thank Christy Waterfall and Mark Gibbs at Illumina UK and Illumina Technical Support staff for their assistance. CO is a Barts Cambridge Molecular Pathology Clinical Research Fellow funded by grant support from Cancer Research UK (MONG1E9R). DO and RL are in receipt of Medical Research Council Clinical Research Fellowships. This work was also supported by funding from Cancer Research UK (programme grant to Centre for Medical London NHS Trust (ONAG1G5R) and by a National Institute of Health Strategic Partnering for Evaluation of Cancer Signatures Program (SPECS) grant (5 U01 CA114778). number-of-cited-references: 48 times-cited: 50 usage-count-last-180-days: 0 usage-count-since-2013: 2 journal-iso: Leukemia doc-delivery-number: 506YX unique-id: ISI:000270816300019 oa: gold_or_bronze da: 2018-08-24
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume23
pubs.embargo.termsNot known
dc.contributor.icrauthorCrook, Timothyen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record